Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2.
暂无分享,去创建一个
[1] J. Folkman,et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.
[2] 居軒 功. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis , 2004 .
[3] Richard O. Hynes,et al. The Extracellular Matrix: Not Just Pretty Fibrils , 2009, Science.
[4] J. Lawler,et al. Thrombospondin-based antiangiogenic therapy. , 2007, Microvascular research.
[5] Yongji Wang,et al. Enhanced proangiogenic signaling in thrombospondin-1-deficient retinal endothelial cells. , 2006, Microvascular research.
[6] D. Wink,et al. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[7] R. Kerbel,et al. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[8] D. Wink,et al. Nitric Oxide and Its Gatekeeper Thrombospondin-1 in Tumor Angiogenesis , 2007, Clinical Cancer Research.
[9] W. Sessa,et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[10] D. Ribatti,et al. Non-peptidic Thrombospondin-1 Mimics as Fibroblast Growth Factor-2 Inhibitors , 2010, The Journal of Biological Chemistry.
[11] J. Lawler,et al. Antiangiogenic Treatment with the Three Thrombospondin-1 Type 1 Repeats Recombinant Protein in an Orthotopic Human Pancreatic Cancer Model , 2005, Clinical Cancer Research.
[12] Tracy T Batchelor,et al. Angiogenesis as a therapeutic target in malignant gliomas. , 2009, The oncologist.
[13] H. Dvorak,et al. Thrombospondin‐1 modulates vascular endothelial growth factor activity at the receptor level , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[14] J. Lawler,et al. ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer , 2009, Molecular Cancer Therapeutics.
[15] J. Lawler,et al. Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. , 2007, Cancer letters.
[16] I. Bernard-Pierrot,et al. Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis , 2004, Oncogene.
[17] B. Griffin,et al. Thrombospondin and in vivo angiogenesis induced by basic fibroblast growth factor or lipopolysaccharide. , 1993, Investigative ophthalmology & visual science.
[18] P. Bornstein,et al. Thrombospondins use the VLDL receptor and a nonapoptotic pathway to inhibit cell division in microvascular endothelial cells. , 2007, Molecular biology of the cell.
[19] D. Roberts,et al. Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies , 2009, Nature Reviews Cancer.
[20] L. Liotta,et al. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor , 1990, The Journal of cell biology.
[21] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[22] P. Wen,et al. Antiangiogenic strategies for treatment of malignant gliomas , 2009, Neurotherapeutics.
[23] O. Volpert,et al. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 , 2000, Nature Medicine.
[24] D. Louis,et al. Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors , 2010, Oncogene.
[25] H. Groen,et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] M. Shibuya,et al. Novel antiangiogenic pathway of thrombospondin‐1 mediated by suppression of the cell cycle , 2007, Cancer science.
[27] R. Khosravi‐Far,et al. A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR. , 2009, Cancer research.
[28] D. Mosher,et al. Differential Interactions of Thrombospondin-1, -2, and -4 with CD47 and Effects on cGMP Signaling and Ischemic Injury Responses* , 2009, Journal of Biological Chemistry.
[29] J. Henkin,et al. The thrombospondin-1 mimetic ABT-510 increases the uptake and effectiveness of cisplatin and paclitaxel in a mouse model of epithelial ovarian cancer. , 2010, Neoplasia.
[30] S. Badylak,et al. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities. , 2005, Journal of medicinal chemistry.
[31] Julia Fukuyama,et al. Thrombospondin-1 Inhibits Nitric Oxide Signaling via CD36 by Inhibiting Myristic Acid Uptake* , 2007, Journal of Biological Chemistry.
[32] J. Vacanti,et al. Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy. , 2002, Cancer research.
[33] G. Demetri,et al. Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] E. Brown,et al. Integrin-associated Protein Is a Receptor for the C-terminal Domain of Thrombospondin (*) , 1996, The Journal of Biological Chemistry.
[35] D. Ingber,et al. Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by β1 integrins , 2005, The Journal of cell biology.
[36] T. Michel,et al. Life history of eNOS: partners and pathways. , 2007, Cardiovascular research.
[37] C. Heeschen,et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells , 2003, Nature Medicine.
[38] H. Rabb,et al. Identification of thrombospondin 1 (TSP-1) as a novel mediator of cell injury in kidney ischemia. , 2005, The Journal of clinical investigation.
[39] R. Tucker. The thrombospondin type 1 repeat superfamily. , 2004, The international journal of biochemistry & cell biology.
[40] M. Karin,et al. c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1 , 2001, Oncogene.
[41] M. Simons,et al. Thrombospondin Type 1 Repeats Interact with Matrix Metalloproteinase 2 , 2000, The Journal of Biological Chemistry.
[42] R. Hynes,et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[43] O. Hudlická,et al. Nitric oxide, VEGF, and VEGFR-2: interactions in activity-induced angiogenesis in rat skeletal muscle. , 2005, American journal of physiology. Heart and circulatory physiology.
[44] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[45] H. Izzedine,et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[46] M. L. Le Beau,et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[47] H. Fathallah-Shaykh,et al. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. , 2010, Archives of Neurology.
[48] R. D'Amato,et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. , 2005, Cancer cell.
[49] R. Silverstein,et al. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. , 2005, Matrix biology : journal of the International Society for Matrix Biology.
[50] P. Bagavandoss,et al. Specific inhibition of endothelial cell proliferation by thrombospondin. , 1990, Biochemical and biophysical research communications.
[51] J. Lawler,et al. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms. , 2001, Cancer research.
[52] T Persson,et al. A marker-free method to estimate joint centre of rotation by video image processing. , 1995, Computer methods and programs in biomedicine.
[53] Shenhong Wu,et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. , 2008, JAMA.
[54] J. Coligan,et al. Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. , 1978, The Journal of biological chemistry.
[55] R. Hebbel,et al. Binding and displacement of vascular endothelial growth factor (VEGF) by thrombospondin: Effect on human microvascular endothelial cell proliferation and angiogenesis , 2004, Angiogenesis.
[56] R. D'Amato,et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. , 2001, Cancer research.
[57] M. Iruela-Arispe. Regulation of thrombospondin1 by extracellular proteases. , 2008, Current drug targets.
[58] M. Danks,et al. Stem and progenitor cell-mediated tumor selective gene therapy , 2008, Gene Therapy.
[59] O. Volpert,et al. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. , 1999, Molecular pharmacology.
[60] R. Jain,et al. Role of eNOS in neovascularization: NO for endothelial progenitor cells. , 2004, Trends in molecular medicine.
[61] G. Lang,et al. Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy. , 2009, Critical reviews in oncology/hematology.
[62] P. Bornstein,et al. Enhanced Angiogenesis and Reduced Contraction in Thrombospondin-2–null Wounds Is Associated With Increased Levels of Matrix Metalloproteinases-2 and −9, and Soluble VEGF , 2009, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[63] David W. Dawson,et al. CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells , 1997, The Journal of cell biology.
[64] J. Lawler,et al. The cell biology of thrombospondin-1. , 2000, Matrix biology : journal of the International Society for Matrix Biology.
[65] J. Lawler,et al. Internalization but not binding of thrombospondin‐1 to low density lipoprotein receptor‐related protein‐1 requires heparan sulfate proteoglycans , 2004, Journal of cellular biochemistry.
[66] E. D. de Vries,et al. Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: a safe combination. , 2006, European journal of cancer.
[67] J. Lawler,et al. Thrombospondin‐1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor‐related protein‐1 (LRP‐1) , 2007, Journal of cellular physiology.
[68] J. Ingle,et al. A Phase II Study of ABT-510 (Thrombospondin-1 Analog) for the Treatment of Metastatic Melanoma , 2007, American journal of clinical oncology.
[69] R. Kerbel,et al. Metronomic Low-Dose Chemotherapy Boosts CD95-Dependent Antiangiogenic Effect of the Thrombospondin Peptide ABT-510: A Complementation Antiangiogenic Strategy , 2005, Clinical Cancer Research.
[70] D. Wink,et al. CD47 Is Necessary for Inhibition of Nitric Oxide-stimulated Vascular Cell Responses by Thrombospondin-1* , 2006, Journal of Biological Chemistry.
[71] Thomas Hawighorst,et al. CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo , 2010, Breast Cancer Research and Treatment.
[72] J. Lawler,et al. Improved Vascular Engraftment and Graft Function After Inhibition of the Angiostatic Factor Thrombospondin-1 in Mouse Pancreatic Islets , 2008, Diabetes.
[73] P. Huang,et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. , 1998, The Journal of clinical investigation.
[74] O. Volpert,et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium–derived factor , 2002, Nature Medicine.
[75] H. Krutzsch,et al. Antiproliferative and antitumor activities of D-reverse peptides derived from the second type-1 repeat of thrombospondin-1. , 2009, The journal of peptide research : official journal of the American Peptide Society.
[76] Erwin G. Van Meir,et al. Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. , 2003, The American journal of pathology.
[77] Ralph Weissleder,et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy , 2009, Proceedings of the National Academy of Sciences.
[78] J. Henkin,et al. ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis , 2007, Cancer biology & therapy.
[79] A. Stopeck,et al. A phase 1 trial of 2 dose schedules of ABT‐510, an antiangiogenic, thrombospondin‐1‐mimetic peptide, in patients with advanced cancer , 2008, Cancer.
[80] G. Tuszynski,et al. Matrix-bound thrombospondin promotes angiogenesis in vitro , 1994, The Journal of cell biology.
[81] M. Iruela-Arispe,et al. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. , 1999, Circulation.
[82] C. Dinney,et al. Inhibition of tumor growth by systemic treatment with thrombospondin‐1 peptide mimetics , 2002, International journal of cancer.
[83] B. Banas,et al. Identification of Novel β1 Integrin Binding Sites in the Type 1 and Type 2 Repeats of Thrombospondin-1* , 2004, Journal of Biological Chemistry.
[84] O. Volpert,et al. Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments. , 2008, Current drug targets.
[85] R K Jain,et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[86] A. Joachimiak,et al. Crystal structure of the TSP-1 type 1 repeats , 2002, The Journal of cell biology.
[87] B. Hopkins,et al. Thrombospondin-1 modulates VEGF-A-mediated Akt signaling and capillary survival in the developing retina. , 2009, American journal of physiology. Heart and circulatory physiology.
[88] D. Wink,et al. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[89] R. Figlin,et al. Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma , 2007, Clinical Cancer Research.
[90] S. Donnini,et al. Role of nitric oxide in the modulation of angiogenesis. , 2003, Current pharmaceutical design.
[91] D. Wink,et al. Blockade of Thrombospondin-1-CD47 Interactions Prevents Necrosis of Full Thickness Skin Grafts , 2008, Annals of surgery.
[92] M. Alessio,et al. ©2005 FASEB The FASEB Journal express article 10.1096/fj.05-3697fje. Published online July 21, 2005. Identification of CD36 molecular features required for its in vitro angiostatic activity , 2022 .
[93] C. Legrand,et al. A recombinant NH(2)-terminal heparin-binding domain of the adhesive glycoprotein, thrombospondin-1, promotes endothelial tube formation and cell survival: a possible role for syndecan-4 proteoglycan. , 2002, Matrix biology : journal of the International Society for Matrix Biology.